ZYME (Zymeworks) Valuation Rank


ZYME Zymeworks Inc ZYME
65 GF Score
Price $25.52
GF Value $23.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zymeworks Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zymeworks Valuation Rank Related Terms

ZYME
65GF Score
Zymeworks Inc ZYME
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $25.52 is trading 9.3% above its estimated GF Value™ of $23.34. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • Valuation Rank:
  • GF Value™: $23.34 vs. price of $25.52 (9.3% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
65GF Score

Get the complete analysis for ZYME

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.52
Price
$23.34
GF Value